Rochelle Strenger

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein, Lyndsay N. Harris, P. Kelly Marcom et al. · Journal of Clinical Oncology · 2003 · 345 citations

Medicine, Oncology, Pharmacology +17

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

William M. Sikov, Don S. Dizon, Rochelle Strenger et al. · Journal of Clinical Oncology · 2009 · 109 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.

Wallace Akerley, W. M. Sikov, F J Cummings et al. · PubMed · 1997 · 34 citations

Medicine, Oncology, Pharmacology +14

Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.

Natalie Sinclair, Maysa Abu‐Khalaf, Tina Rizack et al. · Journal of Clinical Oncology · 2012 · 12 citations

Medicine, Oncology, Pharmacology +17